Prelude Therapeutics Inc
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
PRLD$3.76+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows (Unaudited)
STATEMENTS OF CASH FLOWS
| Three months ended March 31, | ||
|---|---|---|
| (in thousands) | 2026 | 2025 |
| Cash flows used in operating activities: | ||
| Net loss | $(10,385) | $(32,085) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 391 | 435 |
| Noncash lease expense | 387 | 384 |
| Stock-based compensation | 2,000 | 3,832 |
| Amortization of premium and discount on marketable securities, net | (388) | 79 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (561) | (1,048) |
| Accounts payable | (1,879) | (1,910) |
| Deferred revenue | (4,580) | — |
| Accrued expenses and other liabilities | (6,602) | (3,968) |
| Operating lease liabilities | (68) | 50 |
| Net cash used in operating activities | (21,685) | (34,231) |
| Cash flows provided by investing activities: | ||
| Purchases of marketable securities | — | (9,463) |
| Proceeds from maturities of marketable securities | 8,499 | 71,696 |
| Purchases of property and equipment | — | (47) |
| Net cash provided by investing activities | 8,499 | 62,186 |
| Cash flows used in financing activities: | ||
| Payment of withholding taxes related to stock-based compensation to employees | (51) | (5) |
| Payment of offering costs | (294) | — |
| Proceeds from issuance of common stock in connection with the exercise of stock options | 31 | — |
| Principal payments on finance lease liabilities | — | (155) |
| Net cash used in financing activities | (314) | (160) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (13,500) | 27,795 |
| Cash, cash equivalents, and restricted cash at beginning of period | 38,491 | 16,518 |
| Cash, cash equivalents, and restricted cash at end of period | $24,991 | $44,313 |
| Supplemental disclosures of non-cash activities: | ||
| Property and equipment in accounts payable and accrued expenses and other current liabilities | $— | $19 |
| Unrealized loss on marketable securities | $(49) | $(23) |
| Offering costs in accounts payable and accrued expenses and other current liabilities | $144 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.